Evidence map›Paper›PMID 40210238›Full record

ArticleJournal for immunotherapy of cancer2025

Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanoma.

Qian Sun, Nina Wang, Juliane Poelchen, Mareike Peter, Daniel Novak, Feyza Gül Özbay Kurt, Rebekka Bitsch, Huizi Wu, Yiman Wang, Sandra Pardo and 7 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Qian SunSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.ORCID http://orcid.org/0000-0002-4336-7641
Nina WangSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.ORCID http://orcid.org/0009-0001-5410-0248
Juliane PoelchenSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Mareike PeterSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Daniel NovakSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Feyza Gül Özbay KurtSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.ORCID http://orcid.org/0000-0003-4086-6469
Rebekka BitschSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Huizi WuSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Yiman WangSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Sandra PardoSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Rui HanDepartment of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University, Heidelberg, Baden-Württemberg, Germany.ORCID http://orcid.org/0009-0004-8843-9938
Shibo LiuState Key Laboratory of Molecular Oncology, Tsinghua university, School of Basic Medical Sciences, Beijing, China.
Lidong GongPeking University Institute of Systems Biomedicine, Beijing, China.
Yuxin ZhangSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Kilian Wistuba-HamprechtSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany.
Viktor UmanskySkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany j.utikal@dkfz.de v.umansky@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0003-0259-1839
Jochen Sven UtikalSkin Cancer Unit, German Cancer Research Center (DKFZ) and DKFZ Hector Cancer Institute, Heidelberg, Baden-Württemberg, Germany j.utikal@dkfz.de v.umansky@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0001-5316-0241

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeural crest-associated genes play pivotal roles in tumor initiation, progression, and the intricate dynamics of the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSC) within the TME are important in dampening T cell activity and contributing to resistance against immunotherapeutic interventions. The neural crest-associated gene Forkhead Box D1 (FOXD1) has been identified as an oncogenic factor that induces melanoma dedifferentiation and progression. However, the underlying mechanisms and the impact of FOXD1 on the antitumor immune response remain unclear.

methodsTo investigate the impacts of FOXD1 on the melanoma microenvironment, we analyzed publicly available datasets from multiple platforms, including TNMplot, TIMER2.0, etc. In addition, FOXD1 was overexpressed (OE) or knocked down in melanoma cells to identify its biological functions in vitro and in vivo. Flow cytometry and arginase activity assay were used to analyze the phenotype and function of MDSC. Western blot, reverse transcription-PCR, or ELISA assays were employed to analyze the expression of FOXD1 and its downstream effectors. In vivo experiments were conducted to investigate the role of FOXD1 in melanoma progression and the influence on MDSC accumulation within the TME.

resultsWe demonstrate that increased FOXD1 levels inversely correlated with melanoma responsiveness to immunotherapy. Ex-vivo analyses unveiled that monocytes, exposed to conditioned medium from FOXD1-OE melanoma cells, effectively suppressed T cell proliferation and upregulated the expression of programmed death-ligand 1 (PD-L1) and other immunosuppressive factors. FOXD1 was identified as a direct regulator of interleukin 6 (IL6) expression, which is pivotal for MDSC induction. Blocking IL6 reversed MDSC-associated immunosuppression. Additionally, miR-581, a potential negative regulator of FOXD1, attenuated the impact of FOXD1 on IL6 expression and MDSC differentiation. In vivo experiments demonstrated that tumors derived from FOXD1 OE melanoma cells contained a significantly higher frequency of PD-L1

conclusionOur study elucidated a novel function of FOXD1 in melanoma pathogenesis, highlighting its role in orchestrating the immunosuppressive TME by promoting the generation of MDSC via IL6 upregulation.

Indexed as

Forkhead Transcription FactorsMelanomaMyeloid-Derived Suppressor CellsNeural CrestTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceForkhead Transcription FactorsFOXD1 protein, humanImmunosuppressionMyeloid-derived suppressor cell - MDSCSkin CancerTumor microenvironment - TME

Identifiers

PMID40210238
PMCPMC11987097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.